CSL Ltd (CSJ MU) stock market data APIs
€115.6008
0(0%)
as of September 16, 2025
Try our APIs with
free plan!
CSL Ltd Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for CSJ.MU.
Prev. Close
115.6008
Open
115.6008
High
115.6008
Low
115.6008
52 wk Range
114.5-182.7932
Market Cap
86 015 M
Dividends (Yield)
0.0082
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CSL Ltd data using free add-ons & libraries
Get CSL Ltd Fundamental Data
CSL Ltd Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-18
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CSL Ltd News
New
VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment
Full funding of VMX-C001 Phase 3 trial, late-stage product development, manufacturing and pre-launch activities VarmX shareholders to receive initial $117m upfront and further potential milestone paym...
CSL Full Year 2025 Earnings: Misses Expectations
Explore CSL's Fair Values from the Community and select yours CSL (ASX:CSL) Full Year 2025 Results Key Financial Results Revenue: US$15.6b (up 5.1% from FY 2024). Net income: US$3.00b (up 14% from ...
CSL to spin off flu vaccine arm and cut 15% workforce; annual profit rises
(Reuters) -Australian biotech giant CSL Ltd on Tuesday announced plans to demerge its influenza vaccine division, CSL Seqirus, and said it will lay off up to 15% of its workforce, after reporting a st...
Health Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)
ANDEMBRY is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in people with HAE The authorization of ANDEMBRY expands CSL's HAE franchise and underscores th...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
